​

Acumen Pharmaceuticals Stock (NASDAQ:ABOS)

ForecastOwnershipFinancialsChartTranscripts
Acumen Pharmaceuticals by TradingView

Previous Close

$2.67

52W Range

$0.96 - $3.60

50D Avg

$2.80

200D Avg

$2.05

Market Cap

$155.67M

Avg Vol (3M)

$610.46K

Beta

0.34

Div Yield

-

ABOS Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

61

IPO Date

Jul 01, 2021

Website

ABOS Performance

ABOS Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income$-123.83M$-114.02M$-61.14M
Net Income$-121.33M$-102.33M$-52.37M
EBITDA$-123.83M$-98.08M$-51.61M
Basic EPS$-2.00$-1.71$-1.08
Diluted EPS$-2.00$-1.71$-1.08

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts

Q4 25Mar 26, 26 | 12:00 AM
Q3 25Nov 12, 25 | 8:00 AM
Q2 25Aug 12, 25 | 12:00 AM

Peer Comparison

TickerCompany
ACTUActuate Therapeutics Inc
IRDOpus Genetics, Inc.
ALECAlector, Inc.
SPROSpero Therapeutics, Inc.
AGENAgenus Inc.
SEERSeer, Inc.
INOInovio Pharmaceuticals, Inc.
VTGNVistaGen Therapeutics, Inc.
FATEFate Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.